Abstract 1946P
Background
BSar are rare and often present at advanced stage with poor prognosis. Limited data on genomic alterations (GA) exist; we evaluated GA and outcomes in separate cohorts.
Methods
18 (0.2%) pts with Bsar were identified from 11,193 bladder cancers and underwent hybrid capture-based comprehensive genomic profiling (CGP) using DNA only (6 pts) or DNA and RNA seq (12 pts) to assess GA and other biomarkers. Predominant genetic ancestry was assessed using a SNP-based approach and classified as: African (AFR), European (EUR), Central and South American (AMR), South Asian (SAS), or East Asian (EAS). Assessments of tumor mutational burden (TMB), MSI status, genomic signature (GS), gLOH and prediction of germline status were performed. PD-L1 was determined in 2 pts by IHC (1 DAKO 22C3; 1 Ventana SP142). A separate analysis of 317 patients (pts) with stage I-III BSar using NCBD data (2004-2019) was done.
Results
18 Bsar (11 male, median age 66) were included: 12 leiomyosarcomas (LMS), 3 rhabdomyosarcomas (RMS),3 high grade undifferentiated sarcomas (HGS). 16 pts of EUR ancestry, 1 AMR, 1EAS. Mean driver GA frequency was 4.8 (1-10); mean TMB 2.9 mutations/Mb (0-9.6), all MS stable; 1 tumor was PD-L1 negative, the other had 1-49% TPS. Mean gLOH 10.4% (1.7-16.9%). APOBEC GS was noted in 1/12 (8.3%) with 11/12 (91.7%) with no dominant GS. Relevant germline mutations were predicted in RB1 (pt with prior retinoblastoma), VHL (pt with radiation-treated prostate cancer), PTEN (pt with Cowden Syndrome) and MUTYH (pt with intestinal polyposis); 1 pt with prior Wilms tumor had somatic GA only. Most frequently identified GA:TP53 (78%), ATRX (22%), RB1 (22%), PTEN (22%), CDKN2A (17%) and RICTOR, MLL2, DNMT3A, MTAP, KDM6A, TERT, HGF, NF1 (each 11%). In the BSar NCDB cohort (LMS only, overall survival was shorter in pts treated with surgery (S) and chemotherapy (CM), S and radiotherapy (RT) vs with S alone, HR 2.73 (95%CI 1.28-5.80), HR 2.24 (95%CI 1.03-4.88) respectively, after adjusting for sociodemographic and health factors. Age and tumor size had prognostic role.
Conclusions
CGP of Bsar revealed several GA relevant for clinical trial design and germline mutations requiring dedicated germline testing. Limitations: retrospective nature and confounding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J.S. Ross: Financial Interests, Personal, Full or part-time Employment, Medical Director: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche Holdings, Tango Therapeutics, Celsius Therapeutics. P. Grivas: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, BMS, Asieris Pharmaceuticals, Merck KGaA, Seattle Genetics, Aadi Bioscience, Pfizer, Janssen, Boston Gene, Mirati Therapeutics, Exelixis, Genentech/Roche, Gilead Sciences, CG Oncology, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, ImmunityBio, Lucence Health, G1 Therapeutics, Fresenius Kabi, Guardant Health, PureTech, Regeneron Pharmaceuticals, Strata Oncology, Urogen, Silverback Therapeutics, Astellas Pharma; Financial Interests, Institutional, Invited Speaker: Pfizer, Clovis Oncology, Bavarian Nordic, Gilead Sciences, BMS, Debiopharm Group, MSD, QED Therapeutics, GSK, Mirati Therapeutics, G1 Therapeutics, Merck KGaA. D.C. Pavlick: Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche AG. R. Huang: Financial Interests, Personal, Stocks/Shares: Roche. A. Necchi: Financial Interests, Institutional, Research Grant: Merck, AstraZeneca, Ipsen, BMS, Gilead; Financial Interests, Personal, Invited Speaker: Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck, Clovis Oncology; Financial Interests, Invited Speaker: Incyte, Pfizer; Non-Financial Interests, Leadership Role: Global society of Rare Genitourinary Tumors (GSRGT). P. Spiess: Non-Financial Interests, Personal, Leadership Role, Vice Chair For Bladder and Penile Cancer: NCCN. A. Kamat: Financial Interests, Personal, Advisory Board: Merck, Seagen, AstraZeneca, Janssen, CG Oncology, Astellas, Ferring; Financial Interests, Personal, Officer: International Bladder Cancer Group (IBCG); Financial Interests, Institutional, Invited Speaker: CyPRIT; Non-Financial Interests, Leadership Role: IBCG, IBCN; Non-Financial Interests, Member of Board of Directors: AUA; Non-Financial Interests, Advisory Role: EAU. All other authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15